Abstract

Mutations in the glucocerebrosidase 1 (GBA1) gene are related to both Parkinson disease (PD) and Gaucher disease (GD). In both cases, the condition is associated with deficiency of glucocerebrosidase (GCase), the enzyme encoded by GBA1. Ambroxol is a small molecule chaperone that has been shown in mice to cross the blood‐brain barrier, increase GCase activity and reduce alpha‐synuclein protein levels. In this study, we analyze the effect of ambroxol treatment on GCase activity in healthy nonhuman primates. We show that daily administration of ambroxol results in increased brain GCase activity. Our work further indicates that ambroxol should be investigated as a novel therapy for both PD and neuronopathic GD in humans.

Highlights

  • Glucocerebrosidase (GCase) is an enzyme that catalyses the breakdown of glycolipid glucocerebroside to ceramide and glucose, which is encoded by the glucocerebrosidase 1 (GBA1) gene (Beutler, 1992)

  • This study provides the first preliminary data of the effect of ambroxol treatment on GCase activity in different brain regions in wild-type nonhuman primates

  • We observed about a 20% increase in GCase activity in the midbrain, cortex, and striatum of a cynomolgus monkey treated with 100 mg of ambroxol for 28 consecutive days

Read more

Summary

| INTRODUCTION

Glucocerebrosidase (GCase) is an enzyme that catalyses the breakdown of glycolipid glucocerebroside to ceramide and glucose, which is encoded by the glucocerebrosidase 1 (GBA1) gene (Beutler, 1992). Current estimates predict that 5–10% of PD patients carry a GBA1 mutation (PD-GBA1), this figure is much greater in PD patients of Ashkenazi origin (Bultron et al, 2010; Migdalska-Richards and Schapira, 2016; Sidransky et al, 2009). The increasing evidence highlighting the significance of GCase deficiency in both PD-GBA1 and idiopathic PD patients suggests that treatments that increase GCase might be advantageous to PD patients both with and without GBA1 mutations To this end, we have recently investigated a small molecular chaperone, ambroxol hydrochloride (ambroxol), in wild-type mice, in transgenic Gba mice carrying a heterozygous L444P mutation, and in transgenic mice overexpressing human alpha-synuclein (SNCA). We extend this work by analyzing the effect of ambroxol treatment on GCase activity in healthy nonhuman primates

| MATERIAL AND METHODS
| RESULTS
Findings
| DISCUSSION

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.